VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | TROPiCS-02: sacituzumab govetican improves PFS versus physicians choice for HR+/HER2- mBC

Hope Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides an overview of the multicentered randomized Phase III TROPiCS-02 (NCT03901339) trial investigating the antibody-drug conjugate (ADC), sacituzumab govitecan, versus treatment of physicians choice in patients with HR-positive, HER2-negative metastatic breast cancer (mBC) who were heavily pretreated and failed at least two lines of prior therapy. Treatment of physicians choice included capecitabine, gemcitabine or vinorelbine. 543 patients were enrolled onto the trial, almost 100% of which had visceral metastases. The primary endpoint of progression-free survival (PFS) was met and a 34% improvement in PFS was demonstrated in patients treated with sacituzumab govitecan compared to treatment of physicians choice. At 12 months, 21% of patients were free of progression or death with sacituzumab govitecan versus 7% of patients on treatment of physicians choice. A key secondary endpoint is overall-survival (OS), which was not met at the first-interim analysis. Safety was comparable to previous reports on sacituzumab govitecan and quality of life was better with sacituzumab govitecan versus physicians treatment of choice. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter